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To the editor:
Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by
mutation in DNMT3A
Several recent publications reported the occurrence of mutations in
the DNA methyltransferase 3A (DNMT3A) gene in acute myeloid
leukemia (AML).1-3 The majority of DNMT3A mutations identified
affect residue R882 which is located within the methyltransferase
domain.1,2 A strong predilection for leukemias of monocytic or
myelomonocytic lineage was observed.2,3 This, and our previous
findings linking altered DNA methylation patterns with poor
prognosis in juvenile myelomonocytic leukemia (JMML),4 led us
to hypothesize that somatic DNMT3A mutations might also occur
in JMML.
We bidirectionally sequenced DNMT3A exon 23 (containing the
hotspot codon 882) in granulocyte DNA from 113 JMML patients.
All children were enrolled in the European Working Group of MDS
in Childhood (EWOG-MDS) studies 98 or 2006, and informed
consent had been obtained from patients’ guardians. The patients’
median age was 2.0 years. The hotspot mutation DNMT3A
p.R882H was identified in JMML patient D101 (age at diagnosis
6.5 years, somatic NRASG12V mutation; Figure 1A), while all other
samples exhibited wild-type sequence. Epstein-Barr virus-trans-
formed B lymphocytes of D101 carried wild-type sequence,
indicating somatic origin of the DNMT3A mutation.
Although DNMT3A is generally overexpressed in AML blasts
versus healthy leukocytes,5 the expression does not correlate with
occurrence of DNMT3A mutations.1 Despite the finding that
DNMT3A codon 882 mutations lead to reduced enzymatic activity,2
the genome-wide DNA methylation pattern of DNMT3A codon
882-mutant AML cells does not differ significantly from that of
DNMT3A wild-type blasts.1 We measured DNMT3A mRNA expres-
sion in mononuclear cells from 9 JMML patients by quantitative
real-time PCR (RNA from patient D101 was unavailable). The
abundance of the DNMT3A transcript in JMML cells varied
considerably, with some cases expressing DNMT3A at higher levels
than leukocytes from healthy subjects, and others at lower levels
(range, 0.08-14.05 fold; Figure 1B). Unlike in AML where uniform
blast populations are studied, our results may reflect the heteroge-
neous cellular composition of JMML samples. DNA methylation
data were available for 6 of the 9 JMML samples studied,4 but there
was no association of high DNMT3A expression with DNA
hypermethylation (Figure 1C). Remarkably, leukemic cells of
D101 carried hypermethylated BMP4, CALCA and CDKN2B
promoters4 despite the presence of a DNMT3A loss-of-function
mutation.
Several investigators highlighted the possible pathophysiologic
role of the DNA-methylating enzyme DNMT3A in myeloid
malignant disorders other than JMML.1-3,6,7 We conclude that
genetic or transcriptional aberrations of DNMT3A do not contribute
to leukemogenesis in JMML. While the recurrent nature of
DNMT3A alterations in AML, the strong preference to target codon
882 and the prognostic significance argue in favor of non-random
pathogenetic relevance in AML, a DNA methylation profile that
would distinguish DNMT3A-mutant AML cases has not yet been
defined. By contrast, JMML cases with poor outcome exhibit
promoter hypermethylation of several genes4 but for the most part
lack DNMT3A alterations. The data presented here fit well with
previous observations that DNMT3A mutations are much less
prevalent in myeloid malignancies of children than in adults.6,8 In
summary, the functional implication of DNMT3A lesions in my-
eloid leukemogenesis requires further clarification.
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Figure 1. DNMT3A mutation p.R882H in JMML patient D101, DNMT3A
mRNA expression in JMML mononuclear cells and correlation with
promoter DNA methylation. (A) Heterozygous DNMT3A R882H muta-
tion detected in granulocytes but not in Epstein-Barr virus (EBV)–
transformed B cells of patient D101. PB indicates peripheral blood.
(B) Expression of DNMT3A mRNA was measured by quantitative real-time
PCR in mononuclear cells from 9 patients with JMML. Expression in
normal controls (n  4) was averaged and set to 1.0. Each sample was
measured in triplicates; error bars denote 1 SD. (C) Expression of
DNMT3A mRNA and calcitonin A (CALCA) gene promoter DNA methyl-
ation in 6 cases of JMML (methylation data previously published in
Olk-Batz et al4).
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To the editor:
Is there still a place for myeloablative regimen to transplant young adults with sickle cell
disease?
We have read with great interest the comprehensive and detailed
review on hematopoietic stem cell transplantation (HSCT) for
sickle cell disease (SCD) published by Hsieh et al in a recent issue
of the journal.1
As emphasized by the authors, allogeneic HSCT is currently the
only available curative treatment for SCD, but is clearly underuti-
lized. Although it is now considered by many teams as the
“standard of care” for symptomatic children with an HLA identical
sibling, the experience in adults remains very limited.
In their paper, the authors claim that the development of a
SCD-specific transplant regimen based on nonmyeloablative condi-
tioning, along with the use of peripheral blood donor cells and
long-term immunosuppression will provide stable mixed chimer-
ism without rejection or GVHD.2 This innovative approach is
proposed with the implicit rationale that classic transplantation
regimens used for hematologic malignancies are too toxic and
dangerous for SCD adult patients who have accumulated organ
failures and comorbidities before transplant.
We believe that classic myeloablative HSCT regimen has still a
place for young adults with severe SCD, and in this context, we
wish to report the French experience in 15 patients older than
16 years of age (Table 1) who have received geno-identical HSCT
after a full-dose conditioning regimen, 4 of them having been
reported previously.3
All patients received the same BU-CY-ATG regimen3 and
GVHD prophylaxis with short-methotrexate and cyclosporine.
Only 1 death was observed in a patient with severe cerebral
vasculopathy and Moya-Moya who suffered of massive cerebral
hemorrhage at day 32 posttranplant despite a successful engraft-
ment. Seven patients experienced grade 2 and one grade 3
acute-GVHD, quickly resolved with prednisone. Other complica-
tions included seizures, pericarditis, hemorrhagic cystitis, a success-
fully evacuated sub-dural hematoma and an episode of prolonged
but ultimately resolved thrombopenia. Only 2 patients experienced
moderate chronic-GVHD. With a median follow-up of 3.4 years
(range  1-16.1), overall disease-free survival was 93.3%  0.12.
All survivors currently enjoy a normal quality of life without
immunosuppression. Chimerism at 1 year was full-donor in
12 patients and mixed but 75% donor in 2 patients.
Although limited, this experience is the largest so far, and
demonstrates that full myeloablative transplantation has an accept-
able toxicity in selected young adults with SCD. In fact, we did not
observe any unusual complications because of accumulated organ
failures such as veno-occlusive disease or renal failure. The
post-HSCT period had more complex events than in younger
patients but remained manageable. As opposed to nonmyeloabla-
tive transplantation, full-dose regimen carries much less risk of
rejection, does not necessitate prolonged immunosuppressive
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